These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

644 related items for PubMed ID: 21945130

  • 1. Efficacy and safety of the seven-day buprenorphine transdermal system in opioid-naïve patients with moderate to severe chronic low back pain: an enriched, randomized, double-blind, placebo-controlled study.
    Steiner DJ, Sitar S, Wen W, Sawyerr G, Munera C, Ripa SR, Landau C.
    J Pain Symptom Manage; 2011 Dec; 42(6):903-17. PubMed ID: 21945130
    [Abstract] [Full Text] [Related]

  • 2. Buprenorphine transdermal delivery system in adults with persistent noncancer-related pain syndromes who require opioid therapy: a multicenter, 5-week run-in and randomized, double-blind maintenance-of-analgesia study.
    Landau CJ, Carr WD, Razzetti AJ, Sessler NE, Munera C, Ripa SR.
    Clin Ther; 2007 Oct; 29(10):2179-93. PubMed ID: 18042474
    [Abstract] [Full Text] [Related]

  • 3. Efficacy and safety of buprenorphine transdermal system (BTDS) for chronic moderate to severe low back pain: a randomized, double-blind study.
    Steiner D, Munera C, Hale M, Ripa S, Landau C.
    J Pain; 2011 Nov; 12(11):1163-73. PubMed ID: 21807566
    [Abstract] [Full Text] [Related]

  • 4. Transdermal buprenorphine in the treatment of chronic pain: results of a phase III, multicenter, randomized, double-blind, placebo-controlled study.
    Sorge J, Sittl R.
    Clin Ther; 2004 Nov; 26(11):1808-20. PubMed ID: 15639693
    [Abstract] [Full Text] [Related]

  • 5. A randomized, placebo-controlled study of the impact of the 7-day buprenorphine transdermal system on health-related quality of life in opioid-naïve patients with moderate-to-severe chronic low back pain.
    Yarlas A, Miller K, Wen W, Dain B, Lynch SY, Pergolizzi JV, Raffa RB, Ripa SR.
    J Pain; 2013 Jan; 14(1):14-23. PubMed ID: 23200931
    [Abstract] [Full Text] [Related]

  • 6. Transdermal buprenorphine patches applied in a 4-day regimen versus a 3-day regimen: a single-site, Phase III, randomized, open-label, crossover comparison.
    Likar R, Lorenz V, Korak-Leiter M, Kager I, Sittl R.
    Clin Ther; 2007 Aug; 29(8):1591-606. PubMed ID: 17919542
    [Abstract] [Full Text] [Related]

  • 7. Buprenorphine Transdermal System Improves Sleep Quality and Reduces Sleep Disturbance in Patients with Moderate-to-Severe Chronic Low Back Pain: Results from Two Randomized Controlled Trials.
    Yarlas A, Miller K, Wen W, Lynch SY, Ripa SR, Pergolizzi JV, Raffa RB.
    Pain Pract; 2016 Mar; 16(3):345-58. PubMed ID: 25599968
    [Abstract] [Full Text] [Related]

  • 8. Buprenorphine transdermal system and quality of life in opioid-experienced patients with chronic low back pain.
    Miller K, Yarlas A, Wen W, Dain B, Lynch SY, Brennan MJ, Ripa SR.
    Expert Opin Pharmacother; 2013 Feb; 14(3):269-77. PubMed ID: 23374027
    [Abstract] [Full Text] [Related]

  • 9. Oxymorphone extended release for the treatment of chronic low back pain: a retrospective pooled analysis of enriched-enrollment clinical trial data stratified according to age, sex, and prior opioid use.
    Peniston JH, Gould E.
    Clin Ther; 2009 Feb; 31(2):347-59. PubMed ID: 19302907
    [Abstract] [Full Text] [Related]

  • 10. Buprenorphine transdermal system compared with placebo reduces interference in functioning for chronic low back pain.
    Yarlas A, Miller K, Wen W, Lynch SY, Munera C, Pergolizzi JV, Raffa R, Ripa SR.
    Postgrad Med; 2015 Jan; 127(1):38-45. PubMed ID: 25526229
    [Abstract] [Full Text] [Related]

  • 11. Long-term management of chronic pain with transdermal buprenorphine: a multicenter, open-label, follow-up study in patients from three short-term clinical trials.
    Likar R, Kayser H, Sittl R.
    Clin Ther; 2006 Jun; 28(6):943-52. PubMed ID: 16860176
    [Abstract] [Full Text] [Related]

  • 12. Effectiveness and tolerability of the buprenorphine transdermal system in patients with moderate to severe chronic pain: a multicenter, open-label, uncontrolled, prospective, observational clinical study.
    Muriel C, Failde I, Micó JA, Neira M, Sánchez-Magro I.
    Clin Ther; 2005 Apr; 27(4):451-62. PubMed ID: 15922818
    [Abstract] [Full Text] [Related]

  • 13. A randomized, 14-day, double-blind study evaluating conversion from hydrocodone/acetaminophen (Vicodin) to buprenorphine transdermal system 10 μg/h or 20 μg/h in patients with osteoarthritis pain.
    Ripa SR, McCarberg BH, Munera C, Wen W, Landau CJ.
    Expert Opin Pharmacother; 2012 Jun; 13(9):1229-41. PubMed ID: 22409388
    [Abstract] [Full Text] [Related]

  • 14. Efficacy of tramadol in treatment of chronic low back pain.
    Schnitzer TJ, Gray WL, Paster RZ, Kamin M.
    J Rheumatol; 2000 Mar; 27(3):772-8. PubMed ID: 10743823
    [Abstract] [Full Text] [Related]

  • 15. Once-weekly transdermal buprenorphine application results in sustained and consistent steady-state plasma levels.
    Kapil RP, Cipriano A, Friedman K, Michels G, Shet MS, Colucci SV, Apseloff G, Kitzmiller J, Harris SC.
    J Pain Symptom Manage; 2013 Jul; 46(1):65-75. PubMed ID: 23026548
    [Abstract] [Full Text] [Related]

  • 16. Fentanyl buccal tablet for the relief of breakthrough pain in opioid-tolerant adult patients with chronic neuropathic pain: a multicenter, randomized, double-blind, placebo-controlled study.
    Simpson DM, Messina J, Xie F, Hale M.
    Clin Ther; 2007 Apr; 29(4):588-601. PubMed ID: 17617282
    [Abstract] [Full Text] [Related]

  • 17. Efficacy and safety of transdermal buprenorphine: a randomized, placebo-controlled trial in 289 patients with severe cancer pain.
    Poulain P, Denier W, Douma J, Hoerauf K, Samija M, Sopata M, Wolfram G.
    J Pain Symptom Manage; 2008 Aug; 36(2):117-25. PubMed ID: 18411010
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Efficacy and safety of OPANA ER (oxymorphone extended release) for relief of moderate to severe chronic low back pain in opioid-experienced patients: a 12-week, randomized, double-blind, placebo-controlled study.
    Hale ME, Ahdieh H, Ma T, Rauck R, Oxymorphone ER Study Group 1.
    J Pain; 2007 Feb; 8(2):175-84. PubMed ID: 17145204
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 33.